A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of PHP-303 in Otherwise Healthy Overweight or Obese Subjects
| Status: | Recruiting |
|---|---|
| Conditions: | Obesity Weight Loss |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 60 |
| Updated: | 3/15/2019 |
| Start Date: | December 17, 2018 |
| End Date: | August 2019 |
| Contact: | PHP Clinical Operations |
| Email: | clinicaltrials@ph-pharma.com |
| Phone: | 650-549-9100 |
A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PHP-303 in Otherwise Healthy Overweight or Obese Subjects
This is a Phase 1, randomized, double-blind, placebo-controlled multiple-ascending dose (MAD)
study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of PHP-303 in
otherwise healthy overweight or obese volunteer subjects. Within each ascending dose cohort,
subjects will be randomized in a 4:1 ratio to receive PHP-303 or placebo. The primary
objective is to establish the safety and tolerability and maximum tolerated dose (MTD) of
orally-administered PHP-303.
study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of PHP-303 in
otherwise healthy overweight or obese volunteer subjects. Within each ascending dose cohort,
subjects will be randomized in a 4:1 ratio to receive PHP-303 or placebo. The primary
objective is to establish the safety and tolerability and maximum tolerated dose (MTD) of
orally-administered PHP-303.
Inclusion Criteria:
- Male or female subjects, ≥ 18 to ≤ 60 years of age.
- In good general health having no clinically significant diseases in medical history or
evidence of clinically significant findings on physical examination, vital signs,
laboratory results, and/or ECG at Screening, in the opinion of an Investigator.
- Willing to forego other forms of experimental treatment during the study.
Exclusion Criteria:
- Any clinically significant condition that, in the opinion of an Investigator, could
preclude the safe participation of the subject in the study or would prevent the
subject from meeting the study requirements.
- Major surgery in the 6 months preceding Screening.
- Clinically-significant abnormal laboratory parameters.
- Positive urine drug test for alcohol, cotinine, and/or drugs of abuse (cocaine,
tetrahydrocannabinol, amphetamines, methamphetamines, or benzodiazepines) at Screening
or on admission to the study site.
- Electrocardiographic Fridericia's corrected QT interval (QTcF) interval > 450 msec for
males and > 470 msec for females, or any other clinically significant
electrocardiographic abnormality.
- Blood pressure results > 150 mmHg systolic or > 95 mmHg diastolic
- Female subject who is pregnant (positive pregnancy test at the Screening Visit or on
admission to the study site), lactating, or planning to become pregnant during the
study period or within 3 months after the final dose of study medication.
- History of drug or alcohol abuse or dependence within 1 year prior to Screening.
- History of cigarette smoking within 3 months of Screening.
- Known intolerance to lactose.
- Regular use of prescription drugs within 14 days of the first administration of study
drug or non-prescription (over-the-counter) drugs within 7 days of the first
administration of study drug or unwilling to abstain from prohibited medications
through the end of study.
We found this trial at
1
site
Click here to add this to my saved trials
